A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 6087-6093

  Nowakowski, Grzegorz S ^a   McCollum, Andrea K ^b   Ames, Matthew M ^a,b   Mandrekar, Sumithra J ^a   Reid, Joel M ^a   Adjei, Alex A ^a   Toft, David O ^b   Safgren, Stephanie L ^a   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINODEMETHOXY GELDANAMYCIN; CHAPERONE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; RAF PROTEIN; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEAT STRESS; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INFECTION; KIDNEY CANCER; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN TARGETING; SARCOMA; SKIN CANCER; SKIN IRRITATION; STOMATITIS; STRESS; SWEATING; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BENZOQUINONES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; LIFE EXPECTANCY; NEOPLASM STAGING; NEOPLASMS; PATIENT SELECTION;

EID: 33750711384     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1015     Document Type: Article

References (35)

1. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 1997;32:17-29.
2. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002;295:1852-8.
3. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 2001;154:267-73.
4. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997;18:306-60.
5. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001;188:281-90.
6. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
7. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
8. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:555-61.
9. Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003;3:297-300.
10. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
11. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
12. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
13. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
14. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17- (Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer. Drugs 2004;15:377-87.
15. Bagatell R, Khan O, Paine-Murrieta G, et al. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84.
16. Nguyen DM, Lorang D, Chen GA, et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371-8; discussion 78-9.
17. Yang J, Yang JM, Iannone M, et al. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res 2001;61:4010-6.
18. Egorin MJ, Zuhowski EG, Rosen DM, et al. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
19. Egorin MJ, Rosen DM, Wolff JH, et al. Metabolism of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 1998;58:2385-96.
20. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
21. McCollum A, Toft D, Erlichman C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2003, pp. 16.
22. Grem JL, Morrison G, Quo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
23. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
24. Johnson JL, Toft DO. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 1995;9:670-8.
25. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
26. Kaufmann SH. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 2001;296:283-6.
27. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-83.
28. Pespeni M, Hodnett M, Pittet JF. In vivo stress preconditioning. Methods 2005;35:158-64.
29. Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia 2005;21:681-7.
30. Pirkkala L, Nykanen P, Sistonen L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. FASEB J 2001;15:1118-31.
31. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65:10536-44.
32. Basso AD, Solit DB, Chiosis G, et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
33. Arlander SJ, Felts SJ, Wagner JM, et al. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones. J Biol Chem 2006;281:2989-98.
34. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
35. Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27.